Predict your next investment

DiscGenics company logo
HEALTHCARE | Biotechnology
discgenics.com

See what CB Insights has to offer

Founded Year

2007

Stage

Series C | Alive

Total Raised

$66.52M

Last Raised

$50M | 1 yr ago

About DiscGenics

DiscGenics is a spinal therapeutics company using adult human disc-derived stem cells and tissue engineering techniques to treat patients debilitated by degenerative disc disease (DDD).

DiscGenics Headquarter Location

675 Arapeen Dr, Ste. 106

Salt Lake City, Utah, 84108,

United States

801-410-0703

Latest DiscGenics News

08:34 ET DiscGenics Honored by Goldman Sachs for Entrepreneurship

Oct 18, 2021

Chairman and CEO Flagg Flanagan Among 100 Most Intriguing Entrepreneurs at 2021 Builders + Innovators Summit News provided by Share this article Share this article SALT LAKE CITY, Oct. 18, 2021 /PRNewswire/ --  DiscGenics , Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Goldman Sachs (NYSE: GS ) recognized DiscGenics Chairman and CEO Flagg Flanagan as one of the 100 Most Intriguing Entrepreneurs of 2021 at its Builders + Innovators Summit in Healdsburg, California. Goldman Sachs selected Mr. Flanagan as one of 100 entrepreneurs from multiple industries to be honored at the two-day event. Flagg Flanagan, Chairman & CEO of DiscGenics Mr. Flanagan has over 30 years of experience in the medical device field as an entrepreneur, executive and advisor. He has led DiscGenics since its founding in 2007 and has overseen its evolution from pre-clinical to clinical phase with its first product candidate, IDCT (rebonuputemcel), an injectable disc cell therapy, now in clinical trials in the U.S. and Japan for degenerative disc disease (DDD). "I am honored to receive this recognition from Goldman Sachs and to be among such an innovative group of entrepreneurs," said Mr. Flanagan. "I am extremely proud of our team at DiscGenics and remain incredibly excited about the opportunity before us to potentially help millions of patients with debilitating back pain." Prior to DiscGenics, Mr. Flanagan founded Flanagan Instruments, which he built over 24 years into a leading neurosurgical device distribution business before selling it to Itochu International in 2005. Mr. Flanagan is currently on the boards of TrueDigital Systems, Peleton Medical, Triad Life Sciences, Steribite, and the Neurosurgery Research & Education Foundation. He has also served on the boards of the Alliance for Regenerative Medicine, as well as TrueVision Systems and Image Stream Medical, which were acquired by Alcon and Olympus, respectively. "Innovation doesn't happen just anywhere; it thrives where there's a wide range of thoughts and perspectives," said David M. Solomon, Chairman & CEO of Goldman Sachs. "One of our great strengths is our ability to bring together people from different walks of life and to spark conversations today that will lead to breakthroughs tomorrow. The leaders we've chosen to highlight at our Builders + Innovators Summit are truly remarkable, and we are pleased to recognize Flagg Flanagan as one of this year's most intriguing entrepreneurs." In addition to honoring 100 entrepreneurs, the summit consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars. About DiscGenics DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics believes it has a unique opportunity to harness the restorative potential of the human body to heal millions of patients suffering from the debilitating effects of back pain. DiscGenics' first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells derived from intervertebral disc tissue, known as Discogenic Cells, to offer a non-surgical, potentially regenerative solution for the treatment of patients with mild to moderate degenerative disc disease. For more information, visit  discgenics.com . SOURCE DiscGenics, Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing DiscGenics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DiscGenics is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

DiscGenics Patents

DiscGenics has filed 9 patents.

The 3 most popular patent topics include:

  • Bones of the vertebral column
  • Neurosurgery
  • Orthopedic surgical procedures
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/8/2016

11/9/2021

Bones of the vertebral column, Skeletal system, Annular solar eclipses, Orthopedic surgical procedures, Neurosurgery

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/8/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/9/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Bones of the vertebral column, Skeletal system, Annular solar eclipses, Orthopedic surgical procedures, Neurosurgery

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

DiscGenics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DiscGenics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.